Taysha Gene Therapies (NASDAQ:TSHA) Issues Earnings Results

06 May 2026, 15:28 by Amy Steele · The Cerbat Gem

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) released its earnings results on Wednesday. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02), FiscalAI reports.

Here are the key takeaways from Taysha Gene Therapies’ conference call:

Management said a Breakthrough Therapy Type B meeting with the FDA reaffirmed the BLA pathway and endpoints — including the option to pursue approval based on a 6‑month interim analysis — and a BLA‑enabling PPQ campaign started in April and is expected to complete by Q4 2026, with the FDA agreeing clinical and commercial material are comparable to allow data pooling.
Dosing in the REVEAL pivotal and ASPIRE trials is on track to finish in Q2 2026, and Part A reported strong efficacy (high‑dose response rates of 83% at 6 months and 100% at 9 months) with no treatment‑related serious adverse events or dose‑limiting toxicities as of the May cutoff.
Preclinical data (to be presented at ASGCT) showed self‑complementary AAV9 produces ~30‑fold higher neuronal transduction versus single‑stranded AAV9, miniMECP2 is functionally comparable to full‑length MECP2, and NHP studies support lumbar intrathecal delivery as a minimally invasive, scalable CNS route.
Taysha said it has assembled senior commercial leadership and is developing launch, payer, and health‑systems strategies, with additional commercial plans to be shared in the second half of 2026.
Operating spend rose sharply (R&D and G&A), widening the Q1 net loss to $42.4 million from $21.5 million a year earlier, although the company reported $276.6 million in cash, which it expects will fund operations into 2028.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock traded down $0.03 during trading on Wednesday, reaching $6.91. 3,005,222 shares of the company’s stock traded hands, compared to its average volume of 2,748,847. The company has a market capitalization of $1.99 billion, a P/E ratio of -20.40 and a beta of 1.25. The company has a current ratio of 12.23, a quick ratio of 12.23 and a debt-to-equity ratio of 0.20. The firm’s 50-day moving average is $4.99 and its 200 day moving average is $4.90. Taysha Gene Therapies has a 1 year low of $1.85 and a 1 year high of $7.30.

Insider Activity at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $4.46, for a total transaction of $892,000.00. Following the sale, the insider directly owned 1,136,410 shares in the company, valued at approximately $5,068,388.60. This represents a 14.97% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.78% of the company’s stock.

Institutional Trading of Taysha Gene Therapies

A number of institutional investors have recently modified their holdings of TSHA. Marex Group plc purchased a new stake in shares of Taysha Gene Therapies during the 2nd quarter valued at approximately $29,000. E Fund Management Co. Ltd. purchased a new stake in shares of Taysha Gene Therapies during the 2nd quarter valued at approximately $31,000. Tower Research Capital LLC TRC lifted its stake in shares of Taysha Gene Therapies by 156.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock valued at $41,000 after buying an additional 10,742 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Taysha Gene Therapies by 51.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company’s stock worth $43,000 after acquiring an additional 6,350 shares during the period. Finally, Caitong International Asset Management Co. Ltd increased its holdings in Taysha Gene Therapies by 143.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock worth $43,000 after acquiring an additional 4,607 shares during the period. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TSHA has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Friday, March 27th. Needham & Company LLC boosted their target price on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, March 19th. Truist Financial upgraded shares of Taysha Gene Therapies to a “strong-buy” rating in a research note on Wednesday, March 25th. Raymond James Financial reiterated a “strong-buy” rating and issued a $13.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Finally, Chardan Capital reiterated a “buy” rating and issued a $12.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $11.64.

Read Our Latest Stock Report on TSHA

Taysha Gene Therapies Company Profile

(Get Free Report)

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.